CA2439897A1 - Enzyme-activated cytostatic conjugates with integrin ligands - Google Patents

Enzyme-activated cytostatic conjugates with integrin ligands Download PDF

Info

Publication number
CA2439897A1
CA2439897A1 CA002439897A CA2439897A CA2439897A1 CA 2439897 A1 CA2439897 A1 CA 2439897A1 CA 002439897 A CA002439897 A CA 002439897A CA 2439897 A CA2439897 A CA 2439897A CA 2439897 A1 CA2439897 A1 CA 2439897A1
Authority
CA
Canada
Prior art keywords
substituted
radical
unsubstituted
denotes
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002439897A
Other languages
English (en)
French (fr)
Inventor
Hans-Georg Lerchen
Joerg Baumgarten
Andreas Schoop
Markus Albers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2439897A1 publication Critical patent/CA2439897A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002439897A 2001-03-08 2002-03-07 Enzyme-activated cytostatic conjugates with integrin ligands Abandoned CA2439897A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01105350A EP1238678A1 (en) 2001-03-08 2001-03-08 Enzyme-activated cytostatic conjugates with integrin ligands
EP01105350.1 2001-03-08
PCT/EP2002/002501 WO2002072151A1 (en) 2001-03-08 2002-03-07 Enzyme-activated cytostatic conjugates with integrin ligands

Publications (1)

Publication Number Publication Date
CA2439897A1 true CA2439897A1 (en) 2002-09-19

Family

ID=8176682

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002439897A Abandoned CA2439897A1 (en) 2001-03-08 2002-03-07 Enzyme-activated cytostatic conjugates with integrin ligands

Country Status (5)

Country Link
US (2) US7304037B2 (https=)
EP (2) EP1238678A1 (https=)
JP (1) JP2004529118A (https=)
CA (1) CA2439897A1 (https=)
WO (1) WO2002072151A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102453036B (zh) * 2010-10-27 2015-12-02 李红玉 一种喜树碱类化合物及其制备方法和在农药中的用途
US9737556B2 (en) 2014-06-13 2017-08-22 Trustees Of Tufts College FAP-activated therapeutic agents, and uses related thereto
CN106573073B (zh) 2014-06-13 2021-09-28 塔夫茨大学信托人 Fap激活的治疗剂以及其相关用途
EA202191244A1 (ru) * 2018-11-05 2021-10-11 Байер Фарма Акциенгезельшафт Новые цитостатические конъюгаты с лигандами интегрина
CN109575051B (zh) * 2019-01-23 2021-07-27 遵义医科大学 一种天然药物成分修饰衍生物及其抗肿瘤应用
US20230293716A1 (en) 2020-05-08 2023-09-21 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof
WO2023057813A1 (en) 2021-10-04 2023-04-13 Vincerx Pharma Gmbh Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorders
WO2023057814A1 (en) 2021-10-04 2023-04-13 Vincerx Pharma Gmbh Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorders
WO2023057812A1 (en) 2021-10-04 2023-04-13 Vincerx Pharma Gmbh Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorder
JP2025537882A (ja) 2022-11-17 2025-11-20 ハンス-ゲオルク レルケン 腫瘍微小環境において切断可能な小分子-薬物コンジュゲート
GB202407865D0 (en) 2024-06-03 2024-07-17 Elasmogen Ltd Self immolative compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3611194A1 (de) 1986-04-04 1987-10-08 Bayer Ag Cancerostatisches mittel
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4980343A (en) 1988-10-27 1990-12-25 Bayer Aktiengesellschaft Aminooxodihydroisoindoloquinazoline carcinostatic agents
CA2076982A1 (en) 1990-12-27 1992-06-28 Akira Okura Pyridonecarboxylic acid derivatives
US5561116A (en) * 1991-04-11 1996-10-01 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Solid product containing propolis components, and preparation and uses thereof
FR2676058B1 (fr) 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
DE4120646A1 (de) 1991-06-22 1992-12-24 Bayer Ag 7-isoindolinyl-chinolon- und naphthyridoncarbonsaeure-derivate
DE4229903A1 (de) 1992-09-08 1994-03-10 Bayer Ag Neue Acetale von Ketophosphamid und Alkylglycosiden
DE4236237A1 (de) 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
US5646159A (en) 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
DE19512484A1 (de) 1995-04-04 1996-10-17 Bayer Ag Kohlenhydratmodifizierte Cytostatika
CA2265484C (en) * 1996-09-10 2008-12-02 The Burnham Institute Tumor homing molecules, conjugates derived therefrom, and methods of using same
ID23424A (id) 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
JP2002510709A (ja) * 1998-04-08 2002-04-09 ジー・ディー・サール・アンド・カンパニー 二重Avb3及び転移関連受容体リガンド
US6291503B1 (en) 1999-01-15 2001-09-18 Bayer Aktiengesellschaft β-phenylalanine derivatives as integrin antagonists
CA2370245A1 (en) * 1999-05-14 2000-11-23 Boehringer Ingelheim Pharmaceuticals, Inc. Enzyme-activated anti-tumor prodrug compounds
ATE438413T1 (de) * 1999-09-08 2009-08-15 Markus Albers Integrin-vermittelte arzneimittel-zielrichtung

Also Published As

Publication number Publication date
JP2004529118A (ja) 2004-09-24
EP1238678A1 (en) 2002-09-11
WO2002072151A1 (en) 2002-09-19
US20080108576A1 (en) 2008-05-08
EP1372732A1 (en) 2004-01-02
US7304037B2 (en) 2007-12-04
US20020193311A1 (en) 2002-12-19

Similar Documents

Publication Publication Date Title
US20080108576A1 (en) Novel cytostatic conjugates with integrin ligands
JP6539729B2 (ja) ペプチド−薬物複合体
CN104784699A (zh) 叶酸受体结合配体-药物偶联物
CA2267328A1 (en) Glycoconjugates from modified camptothecin derivates (20-o-linkage)
AU744425B2 (en) 20(s) camptothecin glycoconjugates
US20020173468A1 (en) Modified cytostatic agents
EP1235595B1 (en) Integrin-mediated drug targeting
US20200247842A1 (en) Immune-stimulating soluble doxorubicin-conjugated complex
CA3193485A1 (en) Peptidic conjugates of sn38 useful in the treatment of cancer
US20020183256A1 (en) Cytostatic-integrin conjugates having specifically cleavable linking units
US20020173452A1 (en) Cytostatic-glycoconjugates having specifically cleavable linking units
US20070225311A1 (en) 7-T-Butoxyiminomethylcamptothecin Conjugated in Position 20 With Integrin Antagonists
US7220824B1 (en) Integrin-mediated drug targeting
CZ401799A3 (cs) Glykokonjugáty 20(S)-camptothecinu, způsob jejich výroby, jejich použití a léčiva tyto látky obsahující
KR20010012558A (ko) 20(s) 캄프토테신 당결합체

Legal Events

Date Code Title Description
FZDE Discontinued